Conclusions. Conclusions -In patients undergoing primary angioplasty, prophylactic treatment with N-acetylcysteine seems to reduce the rate of contrast-medium.

Slides:



Advertisements
Similar presentations
Unstable angina and NSTEMI
Advertisements

IRMA TRUpoint Creatinine Cartridge Field Launch
Prevention of Contrast-Induced Nephropathy (CIN) Sepehr Khashaei, MD Assistant professor Department of Internal Medicine.
A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic Hemodialysis Presented by Mike Touchy, HO-I.
REMEDIAL II Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): RenalGuard™ System In High-Risk Patients for Contrast-Induced.
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
3. The ASCERTAIN Study. Source Holdaas H, Rostaing L, Serón D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor.
Severe Sepsis Initial recognition and resuscitation
Can we prevent stent restenosis after coronary stent implantation
Journal Club Naudia N. Lauder, M.D. Evan J. Lipson, M.D. David T. Majure, M.D., M.P.H.
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
Ischaemic Heart Disease for the GP Chris Tracey GPVTS.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Dose Adjustment in Renal and Hepatic Disease
Radiocontrast Nephropathy Jason S. Finkelstein, M.D. Tulane University HSC Division of Cardiology 3/2/04.
ARMYDA-CIN Trial [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy]
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit The SAFE Study Investigators N Engl J Med 2004: 350:
IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.
CR-1 Everolimus Benefit/Risk Assessment Howard J. Eisen, MD Thomas J. Vischer Professor of Medicine Chief, Division of Cardiology Drexel University College.
Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Can we protect patients undergoing percutaneous coronary intervention better? Beneficial effects of short- and long-term trimetazidine MR therapy in patients.
ACUTE RENAL FAILURE 吳志仁 醫師 馬偕醫院 腎臟內科. Definition An increase Cr. ≧ 0.5 mg/dl per day An increase of more than 50 % over baseline Cr. A reduction in calculated.
Can we better protect patients who undergo revascularization? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing.
Implementation of RRT improved the survival rate significantly, when blood urea nitrogen or serum creatinine was still low level. However, most of those.
GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Medical Technology and Practice Patterns Institute 4733 Bethesda Ave., Suite #510 Bethesda, MD Phone: Fax: Comparison of.
The DVD Trial. Source Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or.
Retrospective Monocentric 10-Year Analysis Of Sepsis-Associated Acute Kidney Injury: Impact On Outcome, Dialysis Dose And Residual Renal Function 1 Vincenzo.
Special Situations In The Management Of In-Patient Hyperglycemia
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
INCREASED RISK OF MYOCARDIAL INFARCTION AND STROKE FOLLOWING EXACERBATION OF COPD Gavin C. Donaldson, PhD ; John R. Hurst, PhD ; Christopher J. Smith,
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Angela Aziz Donnelly April 5, 2016
Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Risk prediction models of AKI DR.F.Haghverdi MD Outline AKI epidemiology and definition(brenner2016) Biomarkers Risk prediction models of AKI (post CABG,
Bonnie Ky, MD, MSCE Assistant Professor of Medicine and Epidemiology
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Early high-dose Rosuvastatin for
Volume 62, Issue 6, Pages (December 2002)
Management of ST-Elevation Myocardial Infarction
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Regadenoson Use in Chronic Kidney Disease and End-Stage.
RAAS Blockade: Focus on ACEI
Objectives Early initiation of continuous renal replacement therapy
The following slides highlight a report on a presentation at the Late-breaking Trials Session and a Satellite Symposium of the American Heart Association.
Pearls Presentation Use of N-Acetylcysteine For prophylaxis of Radiocontrast Nephrotoxicity.
European Heart Association Journal 2007 April
Atorvastatin for Reduction of Myocardial Damage During Angioplasty
RESEARCH QUESTION: Among critically ill, mechanically ventilated adults, does early in-bed cycling and routine PT compared to routine PT alone improve.
End point Fenoldopam, n (%) Dopamine, n (%) p
AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.
LRC-CPPT and MRFIT Content Points:
Volume 62, Issue 6, Pages (December 2002)
RESEARCH QUESTION: Among critically ill, mechanically ventilated adults, does early in-bed cycling and routine PT compared to routine PT alone improve.
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Conclusions

Conclusions -In patients undergoing primary angioplasty, prophylactic treatment with N-acetylcysteine seems to reduce the rate of contrast-medium induced nephropathy when compared with post-procedure hydration alone -In terms of prevention of contrast medium induced nephropathy, higher doses of N-acetylcysteine seem to be more beneficial, suggesting a dose-dependent effect -Notably, the rate of contrast medium induced nephropathy was independently related to the presence of baseline renal function impairment and more depressed left ventricular dysfunction

Conclusions -Suggestion that because preventive and dose- dependent effects were seen in and throughout the spectrum of renal function ventricular function, that N-acetylcysteine may have a broader range of kidney-protective effects

Implications - Based on previous studies we know that primary angioplasty carries a considerable risk of contrast-medium induced nephropathy suggesting high-dose N-acetylcysteine may play a significant role in decreasing the morbidity and mortality associated with primary angioplasty - We should consider pre- and post- hydration the standard of care when patient are suspected of having to undergo angioplasty - May suggest that pre- and post hydration be the standard when dealing with any patient exposure to contrast medium

Strengths -N-acetylcysteine not previously studied in primary angioplasty N-acetylcysteine can be administer quickly and in bolus form unlike typically hydration schedules -N-acetylcysteine seems to have few side effects and possibly added cardioprotective benefits -Almost all of the in-hospital deaths were from cardiac causes with the exception of multiorgan failure and arrhythmias

Weaknesses -not specific about blinding -limited demographic distribution -not matched for smoking -all patients received post-hydration but question of whether any difference in time to hydration after contrast exposure amongst groups -adjuvant therapy was not standardized -ECHOs were obtained for all patients within 24 hours but over no standardized time period

Weaknesses -question of whether creatinine clearance versus creatinine may have been a better marker of acute renal failure -primary end point was occurrence of contrast- medium induced nephropathy not mortality and composite end of death, acute renal failure requiring temporary dialysis or the need for mechanical ventilation seemed arbitrary and ad hoc -baseline creatinine may not be an accurate baseline

Discussion Points  How reproducible and generalizable is this study?  How does this study affect our clinical care?  Can we extrapolate from this data and justify the use of N-acetylcysteine in all patients being exposed to contrast medium?